KalVista Pharmaceuticals, Inc.

The US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

Pharming is to spend $66m to acquire Swedish biotech Abliva and its lead candidate, KL1333, which the specialist pharma company believes could become a blockbuster treatment for mitochondrial disease